This summary was created by AI, based on 14 opinions in the last 12 months.
Experts generally have a positive outlook on Amgen Inc. (AMGN-Q), citing its strong position in the biotech space, consistent dividend growth, and potential for future earnings and revenue growth. The company's recent acquisition is seen as a positive for its future prospects, and its long-term business outlook is considered favorable.
Pays a 3.2% dividend and trades at a 14x forward PE.
His impression was that the Phase 1 trial did go well. Management emphasized long way to go before it would have a monetary impact. Stock did sell off when earnings released. Still likes it. Recent acquisition will be positive for future earnings and revenue growth. Not expensive. Lots in pipeline.
Drop mainly due to NVO and LLY leading the pack on weight-loss drugs. Still, AMGN has a great lineup of drugs, revenues should grow over time. Ranks well for him. More beta than a normal healthcare stock. Now at 100-day MA, almost oversold. Makes sense from an earnings growth perspective, high single digits. Fine name, he just prefers others.
Down a bit on earnings report this morning, but overlook that, short-term reaction. Phase 1 weight-loss drug primed to compete with LLY's, though not yet being promoted as its next blockbuster. Much more modest multiple than LLY.
Reasonable multiple, mid-high teens. Good growth rate, highly predictable. Has a GLP-1 candidate, good results in Phase 1 testing. 17% of revenue goes back into R&D.
It reports Tuesday If Eli Lilly reports 9also Tuesday) good GLP numbers, he'd buy Amgen.
One of those you just buy today and hold. Pretty volatile. Secular trend in healthcare. Wide moat. 30% free cashflow. Good stock.
They bought a pharma company, luckily wasn't blocked by the FTC. Shares jumped 21% in Q3.
He took some money out of tech and put it into healthcare, which has seen an increase lately. He just added Amgen who delieverd a terrific report. He will continue to rally in the second half this year, will outperform tech.
A long-term fine business and just reported good earnings. It's not in tech or industrials, so it has more stickiness. They made positive plans in their drug pipeline. Seasonally, now is the right time to buy biotech
(Analysts’ price target is $256.05)He bought it last week to diversify and get more exposure in pharmaceuticals. They report next week. Compare to Abbvie which just surprised with drug sales. There's some FT overhang, but shares have been bottoming out recently. If they announce good results, investors will chase this next week.
Facing a patent crisis as proprietary tech is challenged.
Shares have recently sold off.
Will take time to see how prospects play out.
Good hold, but other places to invest for new investors.
Amgen Inc. is a American stock, trading under the symbol AMGN-Q on the NASDAQ (AMGN). It is usually referred to as NASDAQ:AMGN or AMGN-Q
In the last year, 13 stock analysts published opinions about AMGN-Q. 11 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Amgen Inc..
Amgen Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Amgen Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
13 stock analysts on Stockchase covered Amgen Inc. In the last year. It is a trending stock that is worth watching.
On 2024-04-25, Amgen Inc. (AMGN-Q) stock closed at a price of $269.43.
Legacy products that continue to do well. But new products are contributing well, too. Latest acquisition adding significantly to growth profile. Reasonable multiple of 12-13x, good prospects for growth. Out of favour, along with many healthcare stocks. Good, long-term hold.